MedTrace Logo

Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

NCT00155714 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-03-16

No results posted yet for this study

Summary

The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension

Conditions

  • Primary and Secondary Pulmonary Hypertension

Interventions

DRUG

type-5 phosphodiesterase Inhibitor (Sildenafil)

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ping-Hung Kuo, MD · National Taiwan University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Completion
2005-05-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00155714 on ClinicalTrials.gov